International Nonproprietary Names for Pharmaceutical Substances (INN)

RECOMMENDED International Nonproprietary Names: List 64

Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances [*Off. Rec. Wld Health Org.*, 1955, **60**, 3 (Resolution EB15.R7); 1969, **173**, 10 (Resolution EB43.R9); Resolution EB115.R4 (EB115/2005/REC/1)], the following names are selected as Recommended International Nonproprietary Names. The inclusion of a name in the lists of Recommended International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy.
Lists of Proposed (1–101) and Recommended (1–62) International Nonproprietary Names can be found in *Cumulative List No. 13, 2009* (available in CD-ROM only).

Dénominations communes internationales des Substances pharmaceutiques (DCI)

Dénominations communes internationales RECOMMANDÉES: Liste 64

Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de Dénominations communes internationales recommandées pour les Substances pharmaceutiques [*Actes off. Org. mond. Santé*, 1955, **60**, 3 (résolution EB15.R7); 1969, **173**, 10 (résolution EB43.R9); résolution EB115.R4 (EB115/2005/REC/1)] les dénominations ci-dessous sont choisies par l'Organisation mondiale de la Santé en tant que dénominations communes internationales recommandées. L'inclusion d'une dénomination dans les listes de DCI recommandées n'implique aucune recommandation en vue de l'utilisation de la substance correspondante en médecine ou en pharmacie.
On trouvera d'autres listes de Dénominations communes internationales proposées (1–101) et recommandées (1–62) dans la *Liste récapitulative No. 13, 2009* (disponible sur CD-ROM seulement).

Denominaciones Comunes Internacionales para las Sustancias Farmacéuticas (DCI)

Denominaciones Comunes Internacionales RECOMENDADAS: Lista 64

De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones Comunes Internacionales Recomendadas para las Sustancias Farmacéuticas [*Act. Of. Mund. Salud*, 1955, **60**, 3 (Resolución EB15.R7); 1969, **173**, 10 (Resolución EB43.R9); Résolution EB115.R4 (EB115/2005/REC/1) EB115.R4 (EB115/2005/REC/1)], se comunica por el presente anuncio que las denominaciones que a continuación se expresan han sido seleccionadas como Denominaciones Comunes Internacionales Recomendadas. La inclusión de una denominación en las listas de las Denominaciones Comunes Recomendadas no supone recomendación alguna en favor del empleo de la sustancia respectiva en medicina o en farmacia.
Las listas de Denominaciones Comunes Internacionales Propuestas (1–101) y Recomendadas (1–62) se encuentran reunidas en *Cumulative List No. 13, 2009* (disponible sólo en CD-ROM).

Latin, English, French, Spanish: *Recommended INN*	*Chemical name or description; Molecular formula; Graphic formula*
DCI Recommandée	*Nom chimique ou description; Formule brute; Formule développée*
DCI Recomendada	*Nombre químico o descripción; Fórmula molecular; Fórmula desarrollada*


acidum zibrofusidicum

zibrofusidic acid — (17*Z*)-16β-(acetyloxy)-24-bromo-3α,11α-dihydroxy-29-norprotosta-17(20),24-dien-21-oic acid

acide zibrofusidique — acide (17*Z*)-16β-(acétyloxy)-24-bromo-3α,11α-dihydroxy-29-norprotosta-17(20),24-dién-21-oïque

ácido zibrofusídico — ácido (17*Z*)-16β-(acetiloxi)-24-bromo-3α,11α-dihidroxi-29-norprotosta-17(20),24-dien-21-oico

$C_{31}H_{47}BrO_6$




afatinibum

afatinib — (2*E*)-*N*-[4-(3-chloro-4-fluoroanilino)-7-{[(3*S*)-oxolan-3-yl]oxy}quinoxazolin-6-yl]-4-(dimethylamino)but-2-enamide

afatinib — (2*E*)-*N*-[4-(3-chloro-4-fluoroanilino]-7-{[(3*S*)-oxolan-3-yl]oxy}quinoxazolin-6-y]-4-(diméthylamino)but-2-énamide

afatinib — (2*E*)-*N*-[4-(3-cloro-4-fluoroanilino)-7-{[(3*S*)-oxolan-3-il]oxi}quinoxazolin-6-il]-4-(dimetilamino)but-2-enamida

$C_{24}H_{25}ClFN_5O_3$




atagabalinum

atagabalin — [(3*S*,4*S*)-1-(aminomethyl)-3,4-dimethylcyclopent-1-yl]acetic acid

atagabaline — acide [(3*S*,4*S*)-1-(aminométhyl)-3,4-diméthylcyclopent-1-yl]acétique

atagabalina — ácido [(3*S*,4*S*)-1-(aminometil)-3,4-dimetilciclopent-1-il]acético

$C_{10}H_{19}NO_2$




barasertibum

barasertib — 2-{ethyl[3-({4-[(5-{2-[(3-fluorophenyl)amino]-2-oxoethyl}-1*H*-pyrazol-3-yl)amino]quinazolin-7-yl}oxy)propyl]amino}ethyl dihydrogen phosphate

barasertib — dihydrogénophosphate de 2-{éthyl[3-({4-[(5-{2-[(3-fluorophényl)amino]-2-oxoéthyl}-1*H*-pyrazol-3-yl)amino]quinazolin-7-yl}oxy)propyl]aminoéthyle

barasertib — dihidrógenofosfato de 2-{etil[3-({4-[(5-{2-[(3-fluorofenil)amino]-2-oxoetil}-1*H*-pirazol-3-il)amino]quinazolin-7-il}oxi)propil]amino}etilo

$C_{26}H_{31}F\ N_7O_6P$



benralizumabum #

benralizumab — immunoglobulin G1-kappa, anti-[*Homo sapiens* IL5RA (interleukin 5 receptor subunit alpha, CD125)], humanized monoclonal antibody;gamma1 heavy chain (1-451) [humanized VH (*Homo sapiens* IGHV1-46*01 (78.60%) -(IGHD)-IGHJ4*01) [8.8.14] (1-121) -*Homo sapiens* IGHG1*01 (122-451)], (224-214')-disulfide with kappa light chain (1'-214') [humanized V-KAPPA (*Homo sapiens* IGKV1-39*01 (87.40%) -IGKJ2*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')]; (230-230":233-233")-bisdisulfide dimer

benralizumab — immunoglobuline G1-kappa, anti-[*Homo sapiens* ILR5A (sous-unité alpha du récepteur de l'interleukine 5, CD125)], anticorps monoclonal humanisé; chaîne lourde gamma1 (1-451) [VH humanisé (*Homo sapiens* IGHV1-46*01 (78.60%) -(IGHD)-IGHJ4*01) [8.8.14] (1-121) -*Homo sapiens* IGHG1*01 (122-451)], (224-214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA humanisé (*Homo sapiens* IGKV1-39*01 (87.40%) -IGKJ2*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')]; dimère (230-230":233-233")-bisdisulfure

benralizumab

inmunoglobulina G1-kappa, anti-[*Homo sapiens* ILR5A (subunidad alfa del receptor de la interleukina 5, CD125)], anticuerpo monoclonal humanizado;
cadena pesada gamma1 (1-451) [VH humanizada (*Homo sapiens* IGHV1-46*01 (78.60%) -(IGHD)-IGHJ4*01) [8.8.14] (1-121) -*Homo sapiens* IGHG1*01 (122-451)], (224-214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA humanizada (*Homo sapiens* IGKV1-39*01 (87.40%) -IGKJ2*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')]; dímero (230-230":233-233")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVQSGAE VKKPGASVKV SCKASGYTFT SYVIHWVRQR PGQGLAWMGY  50
INPYNDGTKY NERFKGKVTI TSDRSTSTVY MELSSLRSED TAVYLCGREG 100
IRYYGLLGDY WGQGTLVTVS SASTKGPSVF PLAPSSKSTS GGTAALGCLV 150
KDYFPEPVTV SWNSGALTSG VHTFPAVLQS SGLYSLSSVV TVPSSSLGTQ 200
TYICNVNHKP SNTKVDKKVE PKSCDKTHTC PPCPAPELLG GPSVFLFPPK 250
PKDTLMISRT PEVTCVVVDV SHEDPEVKFN WYVDGVEVHN AKTKPREEQY 300
NSTYRVVSVL TVLHQDWLNG KEYKCKVSNK ALPAPIEKTI SKAKGQPREP 350
QVYTLPPSRD ELTKNQVSLT CLVKGFYPSD IAVEWESNGQ PENNYKTTPP 400
VLDSDGSFFL YSKLTVDKSR WQQGNVFSCS VMHEALHNHY TQKSLSLSPG 450
K                                                       451
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS LSASVGDRVT ITCGTSEDII NYLNWYQQKP GKAPKLLIYH  50
TSRLQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ GYTLPYTFGQ 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

```
Intra-H  22-96    148-204   265-325   371-429
         22"-96"  148"-204" 265"-325" 371"-429"
Intra-L  23'-88'   134'-194'
         23'"-88'" 134'"-194'"
Inter-H-L  224-214'  224"-214'"
Inter-H-H  230-230"  233-233"
```

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
301, 301"

cabiotraxetanum

cabiotraxetan

2,2',2''-[10-(2-{[6-({5-[(3a*S*,4*S*,6a*R*)-2-oxohexahydro-1*H*-thieno[3,4-*d*]imidazol-4-yl]pentyl}amino)hexyl]amino}-2-oxoethyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl]triacetic acid


cabiotraxétan

acide 2,2',2''-[10-(2-{[6-({5-[(3a*S*,4*S*,6a*R*)-2-oxohexahydro-1*H*--thiéno[3,4-*d*]imidazol-4-yl]pentyl}amino)hexyl]amino}-2-oxoéthyl)-1,4,7,10-tétraazacyclododécane-1,4,7-triyl]triacétique

cabiotraxetán

ácido [10-(2-{[6-({5-[(3a*S*,4*S*,6a*R*)-2-oxohexahidro-1*H*-tieno[3,4-*d*]imidazol-4-il]pentil}amino)hexil]amino}-2-oxoetil)-1,4,7,10-tetraazaciclododecano-1,4,7-triilo]triacético


$C_{32}H_{58}N_8O_8S$



canagliflozinum

canagliflozin	(1*S*)-1,5-anhydro-1-*C*-(3-{[5-(4-fluorophenyl)thiophen-2-yl]methyl}-4-methylphenyl)-D-glucitol
canagliflozine	(1*S*)-1,5-anhydro-1-*C*-(3-{[5-(4-fluorophényl)thiophén-2-yl]méthyl}-4-méthylphényl)-D-glucitol
canagliflozina	(1*S*)-1,5-anhidro-1-*C*-(3-{[5-(4-fluorofenil)tiofen-2-il]metil}-4-metilfenil)-D-glucitol


$C_{24}H_{25}FO_5S$



carotegrastum

carotegrast	(2*S*)-2-(2,6-dichlorobenzamido)-3-{4-[6-(dimethylamino)-1-methyl-2,4-dioxo-1,4-dihydroquinazolin-3(2*H*)-yl]phenyl}propanoic acid
carotégrast	acide (2*S*)-2-(2,6-dichlorobenzamido)-3-{4-[6-(diméthylamino)-1-méthyl-2,4-dioxo-1,4-dihydroquinazolin-3(2*H*)-yl]phényl}propanoïque
carotegrast	ácido (2*S*)-2-(2,6-diclorobenzamido)-3-{4-[6-(dimetilamino)-1-metil-2,4-dioxo-1,4-dihidroquinazolin-3(2*H*)-il]fenil}propanoico

$C_{27}H_{24}Cl_2N_4O_5$



condoliasum #

condoliase — endolyase, chondroitin ABC (C-ABC). glycosaminoglycan lyase chondroitin ABC endolyase 1 (chondroitinase ABC) *Proteus vulgaris*

condoliase — endolyase, chondroïtine ABC (C-ABC). glycosaminoglycane lyase chondroïtine ABC endolyase 1 (chondroïtinase ABC) *Proteus vulgaris*

condoliasa — endoliasa, condroitina ABC (C-ABC). glicosaminoglicano liasa condroitina ABC endoliasa 1 (condroitinasa ABC) *Proteus vulgaris*

$C_{5039}H_{7770}N_{1360}O_{1525}S_{22}$

```
ATSNPAFDPK  NLMQSEIYHF  AQNNPLADFS  SDKNSILTLS  DKRSIMGNQS   50
LLWKWKGGSS  FTLHKKLIVP  TDKEASKAWG  RSSTPVFSFW  LYNEKPIDGY  100
LTIDFGEKLI  STSEAQAGFK  VKLDFTGWRA  VGVSLNNDLE  NREMTLNATN  150
TSSDGTQDSI  GRSLGAKVDS  IRFKAPSNVS  QGEIYIDRIM  FSVDDARYQW  200
SDYQVKTRLS  EPEIQFHNVK  PQLPVTPENL  AAIDLIRQRL  INEFVGGEKE  250
TNLALEENIS  KLKSDFDALN  IHTLANGGTQ  GRHLITDKQI  IIYQPENLNS  300
QDKQLFDNYV  ILGNYTTLMF  NISRAYVLEK  DPTQKAQLKQ  MYLLMTKHLL  350
DQGFVKGSAL  VTTHHWGYSS  RWWYISTLLM  SDALKEANLQ  TQVYDSLLWY  400
SREFKSSFDM  KVSADSSDLD  YFNTLSRQHL  ALLLLEPDDQ  KRINLVNTFS  450
HYITGALTQV  PPGGKDGLRP  DGTAWRHEGN  YPGYSFPAFK  NASQLIYLLR  500
DTPFSVGESG  WNNLKKAMVS  AWIYSNPEVG  LPLAGRHPFN  SPSLKSVAQG  550
YYWLAMSAKS  SPDKTLASIY  LAISDKTQNE  STAIFGETIT  PASLPQGFYA  600
FNGGAFGIHR  WQDKMVTLKA  YNTNVWSSEI  YNKDNRYGRY  QSHGVAQIVS  650
NGSQLSQGYQ  QEGWDWNRME  GATTIHLPLK  DLDSPKPHTL  MQRGERGFSG  700
TSSLEGQYGM  MAFNLIYPAN  LERFDPNFTA  KKSVLAADNH  LIFIGSNINS  750
SDKNKNVETT  LFQHAITPTL  NTLWINGQKI  ENMPYQTTLQ  QGDWLIDSNG  800
NGYLITQAEK  VNVSRQHQVS  AENKNRQPTE  GNFSSAWIDH  STRPKDASYE  850
YMVFLDATPE  KMGEMAQKFR  ENNGLYQVLR  KDKDVHIILD  KLSNVTGYAF  900
YQPASIEDKW  IKKVNKPAIV  MTHRQKDTLI  VSAVTPDLNM  TRQKAATPVT  950
INVTINGKWQ  SADKNSEVKY  QVSGDNTELT  FTSYFGIPQE  IKLSPLP     997
```

dalotuzumabum #

dalotuzumab — immunoglobulin G1-kappa, anti-[*Homo sapiens* IGF1R (insulin-like growth factor 1 receptor, IGF1-R, IGF-1R, CD221], humanized monoclonal antibody;
gamma1 heavy chain (1-447) [humanized VH (*Homo sapiens* IGHV4-61*08 (79.80%) -(IGHD)-IGHJ4*01) [9.7.10] (1-117) -*Homo sapiens* IGHG1*03 (118-447)], (220-219')-disulfide with kappa light chain (1'-219') [humanized V-KAPPA (*Homo sapiens* IGKV2-29*02 (78.00%) -IGKJ1*01) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01 (113'-219')]; (226-226":229-229")-bisdisulfide dimer

dalotuzumab — immunoglobuline G1-kappa, anti-[*Homo sapiens* IGF1R (récepteur du facteur de croissance 1 analogue à l'insuline (IGF1-R, IGF-1R, CD221)], anticorps monoclonal humanisé;
chaîne lourde gamma1 (1-447) [VH humanisé (*Homo sapiens* IGHV4-61*08 (79.80%) -(IGHD)-IGHJ4*01) [9.7.10] (1-117) -*Homo sapiens* IGHG1*03 (118-447)], (220-219')-disulfure avec la chaîne légère kappa (1'-219') [V-KAPPA humanisé (*Homo sapiens* IGKV2-29*02 (78.00%) -IGKJ1*01) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01 (113'-219')]; dimère (226-226":229-229")-bisdisulfure

dalotuzumab — inmunoglobulina G1-kappa, anti-[*Homo sapiens* IGF1R (receptor del factor de crecimiento similar a la insulina 1(IGF1-R, IGF-1R, CD221)], anticuerpo monoclonal humanizado;
cadena pesada gamma1 (1-447) [VH humanizada (*Homo sapiens* IGHV4-61*08 (79.80%) -(IGHD)-IGHJ4*01) [9.7.10] (1-117) -*Homo sapiens* IGHG1*03 (118-447)], (220-219')-disulfuro con la cadena ligera kappa (1'-219') [V-KAPPA humanizada (*Homo sapiens* IGKV2-29*02 (78.00%) -IGKJ1*01) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01 (113'-219')]; dímero (226-226":229-229")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLQQSGPG LVKPSQTLSL TCTVSGWSIS GGWLWNWIRQ PPGKGLQWIG  50
WISWDGTNNW KPSLKDRVTI SVDTSKNQFS LKLSSVTAAD TAVWWCARWG 100
RVFFDWWGQG TLVTVSSAST KGPSVFPLAP SSKSTSGGTA ALGCLVKDYF 150
PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS SSLGTQTYIC 200
NVNHKPSNTK VDKRVEPKSC DKTHTCPPCP APELLGGPSV FLFPPKPKDT 250
LMISRTPEVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK PREEQYNSTY 300
RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK GQPREPQVYT 350
LPPSREEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS 400
DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS LSLSPGK    447
```

Light chain / Chaîne légère / Cadena ligera

```
DIVMTQSPLS LPVTPGQPAS ISCRSSQSIV HSNGNTWLQW WLQKPGQSPQ  50
LLIWKVSNRL WGVPDRFSGS GSGTDFTLKI SRVQAQDVGV WWCFQGSHVP 100
WTFGQGTKVQ IKRTVAAPSV FIFPPSDEQL KSGTASVVCL LNNFYPREAK 150
VQWKVDNALQ SGNSQESVTE QDSKDSTYSL SSTLTLSKAD YEKHKVYACE 200
VTHQGLSSPV TKSFNRGEC                                   219
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H 22-96 144-200 261-321 367-425
22"-96" 144"-200" 261"-321" 367"-425"
Intra-L 23'-93' 139'-199'
23'"-93'" 139'"-199'"
Inter-H-L 220-219' 220"-219'"
Inter-H-H 226-226" 229-229"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
297, 297"

danoprevirum

danoprevir

(2*R*,6*S*,12*Z*,13a*S*,14a*R*,16a*S*)-6-[(*tert*-butoxycarbonyl)amino]-14a-[*N*-(cyclopropanesulfonyl)carbamoyl]-5,16-dioxo-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[*e*]pyrrolo[1,2-*a*][1,4]diazacyclopentadecin-2-yl 4-fluoro-1,3-dihydro-2*H*-isoindole-2-carboxylate


danoprévir

4-fluoro-1,3-dihydro-2*H*-isoindole-2-carboxylate de (2*R*,6*S*,12*Z*,13a*S*,14a*R*,16a*S*)-6-[(*tert*-butoxycarbonyl)amino]-14a-[*N*-(cyclopropanesulfonyl)carbamoyl]-5,16-dioxo-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadécahydrocyclopropa[*e*]pyrrolo[1,2-*a*][1,4]diazacyclopentadécin-2-yle

danoprevir

4-fluoro-1,3-dihidro-2*H*-isoindol-2-carboxilato de (2*R*,6*S*,12*Z*,13a*S*,14a*R*,16a*S*)-6-[(*terc*-butoxicarbonil)amino]-14a-[*N*-(ciclopropanosulfonil)carbamoil]-5,16-dioxo-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahidrociclopropa[*e*]pirrolo[1,2-*a*][1,4]diazaciclopentadecin-2-ilo

$C_{35}H_{46}FN_5O_9S$




derenofyllinum

derenofylline — *trans*-4-[(2-phenyl-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl)amino]cyclohexanol

dérénofylline — *trans*-4-[(2-phényl-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl)amino]cyclohexanol

derenofilina — *trans*-4-[(2-fenil-7*H*-pirrolo[2,3-*d*]pirimidin-4-il)amino]ciclohexanol

$C_{18}H_{20}N_4O$




dilmapimodum

dilmapimod — 8-(2,6-difluorophenyl)-2-[(1,3-dihydroxypropan-2-yl)amino]-4-(4-fluoro-2-methylphenyl)pyrido[2,3-*d*]pyrimidin-7(8*H*)-one

dilmapimod — 8-(2,6-difluorophényl)-2-[(1,3-dihydroxypropan-2-yl)amino]-4-(4-fluoro-2-méthylphényl)pyrido[2,3-*d*]pyrimidin-7(8*H*)-one

dilmapimod — 8-(2,6-difluorofenil)-2-[(1,3-dihidroxipropan-2-il)amino]-4-(4-fluoro-2-metilfenil)pirido[2,3-*d*]pirimidin-7(8*H*)-ona

$C_{23}H_{19}F_3N_4O_3$




dinaciclibum

dinaciclib — 3-[({3-ethyl-5-[(2*S*)-2-(2-hydroxyethyl)piperidin-1-yl]pyrazolo[1,5-*a*]pyrimidin-7-yl}amino)methyl]pyridine 1-oxide

dinaciclib — 1-oxyde de 3-[({3-éthyl-5-[(2*S*)-2-(2-hydroxyéthyl)pipéridin-1-yl]pyrazolo[1,5-*a*]pyrimidin-7-yl}amino)méthyl]pyridine

dinaciclib — 1-óxido de 3-[({3-etil-5-[(2*S*)-2-(2-hidroxietil)piperidin-1-il]pirazolo[1,5-*a*]pirimidin-7-il}amino)metil]piridina


$C_{21}H_{28}N_6O_2$



dipraglurantum

dipraglurant	6-fluoro-2-[4-(pyridin-2-yl)but-3-yn-1-yl]imidazo[1,2-*a*]pyridine
dipraglurant	6-fluoro-2-[4-(pyridin-2-yl)but-3-yn-1-yl]imidazo[1,2-*a*]pyridine
dipraglurant	6-fluoro-2-[4-(piridin-2-il)but-3-in-1-il]imidazo[1,2-*a*]piridina


$C_{16}H_{12}FN_3$



duvoglustatum

duvoglustat	(2*R*,3*R*,4*R*,5*S*)-2-(hydroxymethyl)piperidine-3,4,5-triol
duvoglustat	(2*R*,3*R*,4*R*,5*S*)-2-(hydroxyméthyl)pipéridine-3,4,5-triol
duvoglustat	(2*R*,3*R*,4*R*,5*S*)-2-(hidroximetil)piperidina-3,4,5-triol


$C_6H_{13}NO_4$



efatutazonum

efatutazone	*rac*-5-[(4-{[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1*H*-benzimidazol-2-yl]methoxy}phenyl)methyl]-1,3-thiazolidine-2,4-dione
éfatutazone	*rac*-5-[(4-{[6-(4-amino-3,5-diméthylphénoxy)-1-méthyl-1*H*-benzimidazol-2-yl]méthoxy}phényl)méthyl]thiazolidine-2,4-dione
efatutazona	*rac*-5-[(4-{[6-(4-amino-3,5-dimetilfenoxi)-1-metil-1*H*-benzoimidazol-2-il]metoxi}fenil)metil]-1,3-tiazolidina-2,4-diona

$C_{27}H_{26}N_4O_4S$




and enantiomer
et énantiomère
y enantiómero

emicerfontum
emicerfont — 1-{1-[1-(4-methoxy-2-methylphenyl)-6-methyl-2,3-dihydro-1*H*-pyrrolo[2,3-*b*]pyridin-4-yl]-1*H*-pyrazol-3-yl}imidazolidin-2-one

emicerfont — 1-{1-[1-(4-méthoxy-2-méthylphényl)-6-méthyl-2,3-dihydro-1*H*-pyrrolo[2,3-*b*]pyridin-4-yl]-1*H*-pyrazol-3-yl}imidazolidin-2-one

emicerfont — 1-{1-[1-(4-metoxi-2-metilfenil)-6-metil-2,3-dihidro-1*H*-pirrolo[2,3-*b*]piridin-4-il]-1*H*-pirazol-3-il}imidazolidin-2-ona

$C_{22}H_{24}N_6O_2$




florbetabenum (^{18}F)
florbetaben (^{18}F) — 4-{(1*E*)-2-(4-{2-[2-(2-[^{18}F]fluoroethoxy)ethoxy]ethoxy}phenyl)eth-1-en-1-yl}-*N*-methylaniline

florbétabène (^{18}F) — 4-{(1*E*)-2-(4-{2-[2-(2-[^{18}F]fluoroéthoxy)éthoxy]éthoxy}phényl)éth-1-én-1-yl}-*N*-méthylaniline

florbetabén (^{18}F) — 4-{(1*E*)-2-(4-{2-[2-(2-[^{18}F]fluoroetoxi)etoxi]etoxi}fenil)et-1-en-1-il}-*N*-metilanilina


$C_{21}H_{26}[^{18}F]NO_3$



foretinibum

foretinib	*N*-[3-fluoro-4-({6-methoxy-7-[3-(morpholin-4-yl)propoxy]quinolin-4-yl}oxy)phenyl]-*N'*-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
forétinib	*N*-[3-fluoro-4-({6-méthoxy-7-[3-(morpholin-4-yl)propoxy]quinoléin-4-yl}oxy)phényl]-*N'*-(4-fluorophényl)cyclopropane-1,1-dicarboxamide
foretinib	*N*-[3-fluoro-4-({6-metoxi-7-[3-(morfolin-4-il)propoxi]quinolin-4-il}oxi)fenil]-*N'*-(4-fluorofenil)ciclopropano-1,1-dicarboxamida

$C_{34}H_{34}F_2N_4O_6$



glembatumumabum #

glembatumumab	immunoglobulin G2-kappa, anti-[*Homo sapiens* GPNMB (glycoprotein transmembrane NMB, hematopoietic growth factor inducible neurokinin-1 type, HGFIN) extracellular domain], *Homo sapiens* monoclonal antibody; gamma2 heavy chain (1-445) [*Homo sapiens* VH (IGHV4-31*02 (94.90%) -(IGHD)-IGHJ4*01) [10.7.11] (1-119) -IGHG2*01 (120-445)], (133-215')-disulfide with kappa light chain (1'-215') [*Homo sapiens* V-KAPPA (IGKV3-15*01 (96.80%) -IGKJ1*01) [6.3.10] (1'-108') -IGKC*01 (109'-215')]; (221-221'':222-222'':225-225'':228-228'')-tetrakisdisulfide dimer
glembatumumab	immunoglobuline G2-kappa, anti-[*Homo sapiens* GPNMB (glycoprotéine transmembranaire NMB, facteur de croissance hématopoïétique inductible type neurokinine-1, HGFIN) domaine extracellulaire], *Homo sapiens* anticorps monoclonal; chaîne lourde gamma2 (1-445) [*Homo sapiens* VH (IGHV4-31*02 (94.90%) -(IGHD)-IGHJ4*01) [10.7.11] (1-119) -IGHG2*01 (120-445)], (133-215')-disulfure avec la chaîne légère kappa (1'-215') [*Homo sapiens* V-KAPPA (IGKV3-15*01 (96.80%) -IGKJ1*01) [6.3.10] (1'-108') -IGKC*01 (109'-215')]; dimère (221-221'':222-222'':225-225'':228-228'')-tétrakisdisulfure
glembatumumab	inmunoglobulina G2-kappa, anti-[*Homo sapiens* GPNMB (glicoproteína transmembranosa NMB, factor de crecimiento hematopoyético inductible tipo neuroquinina-1, HGFIN) dominio extracelular], *Homo sapiens* anticuerpo monoclonal; cadena pesada gamma2 (1-445) [*Homo sapiens* VH (IGHV4-31*02 (94.90%)-(IGHD)-IGHJ4*01) [10.7.11] (1-119) -IGHG2*01 (120-445)], (133-215')-disulfuro con la cadena ligera kappa (1'-215') [*Homo sapiens* V-KAPPA (IGKV3-15*01 (96.80%)-IGKJ1*01) [6.3.10] (1'-108') -IGKC*01 (109'-215')]; dímero (221-221'':222-222'':225-225'':228-228'')-tetrakisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLQESGPG LVKPSQTLSL TCTVSGGSIS SFNYYWSWIR HHPGKGLEWI  50
GYIYYSGSTY SNPSLKSRVT ISVDTSKNQF SLTLSSVTAA DTAVYYCARG 100
YNWNYFDYWG QGTLVTVSSA STKGPSVFPL APCSRSTSES TAALGCLVKD 150
YFPEPVTVSW NSGALTSGVH TFPAVLQSSG LYSLSSVVTV PSSNFGTQTY 200
TCNVDHKPSN TKVDKTVERK CCVECPPCPA PPVAGPSVFL FPPKPKDTLM 250
ISRTPEVTCV VVDVSHEDPE VQFNWYVDGV EVHNAKTKPR EEQFNSTFRV 300
VSVLTVVHQD WLNGKEYKCK VSNKGLPAPI EKTISKTKGQ PREPQVYTLP 350
PSREEMTKNQ VSLTCLVKGF YPSDIAVEWE SNGQPENNYK TTPPMLDSDG 400
SFFLYSKLTV DKSRWQQGNV FSCSVMHEAL HNHYTQKSLS LSPGK      445
```

Light chain / Chaîne légère / Cadena ligera

```
EIVMTQSPAT LSVSPGERAT LSCRASQSVD NNLVWYQQKP GQAPRLLIYG  50
ASTRATGIPA RFSGSGSGTE FTLTISSLQS EDFAVYYCQQ YNNWPPWTFG 100
QGTKVEIKRT VAAPSVFIFP PSDEQLKSGT ASVVCLLNNF YPREAKVQWK 150
VDNALQSGNS QESVTEQDSK DSTYSLSSTL TLSKADYEKH KVYACEVTHQ 200
GLSSPVTKSF NRGEC                                       215
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H 22-97 146-202 259-319 365-423
22"-97" 146"-202" 259"-319" 365"-423"
Intra-L 23'-88' 135'-195'
23'"-88'" 135'"-195'"
Inter-H-L 133-215' 133"-215'"
Inter-H-H 221-221" 222-222" 225-225" 228-228"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
295, 295"


guaraprolosum

guaraprolose — (1→6)-α-D-galactopyrano-(1→4)-β-D-mannopyranan 2-hydroxypropyl ether

guaraprolose — éther 2-hydroxypropylique du (1→6)-α-D-galactopyrano-(1→4)-β-D-mannopyranane

guaraprolosa — éter 2-hidroxipropílico de (1→6)-α-D-galactopirano-(1→4)-β-D-mannopiranano

$[C_{18}H_{30}O_{15}\ (C_3H_6O)_x]_n$



R = H, CH_2-CHOH-CH_3


lasmiditanum

lasmiditan — 2,4,6-trifluoro-*N*-{6-[(1-methylpiperidine-4-yl)carbonyl]pyridin-2-yl}benzamide

lasmiditan — 2,4,6-trifluoro-*N*-{6-[(1-méthylpipéridine-4-yl)carbonyl]pyridin-2-yl}benzamide

lasmiditán — 2,4,6-trifluoro-*N*-{6-[(1-metilpiperidina-4-il)carbonil]piridin-2-il}benzamida


$C_{19}H_{18}F_3N_3O_2$



latrepirdinum

latrepirdine	2,8-dimethyl-5-[2-(6-methylpyridin-3-yl)ethyl]-2,3,4,5-tetrahydro-1*H*-pyrido[4,3-*b*]indole
latrépirdine	2,8-diméthyl-5-[2-(6-méthylpyridin-3-yl)éthyl]-2,3,4,5-tétrahydro-1*H*-pyrido[4,3-*b*]indole
latrepirdina	2,8-dimetil-5-[2-(6-metilpiridin-3-il)etil]-2,3,4,5-tetrahidro-1*H*-pirido[4,3-*b*]indol


$C_{21}H_{25}N_3$



linifanibum

linifanib	1-[4-(3-amino-1*H*-indazol-4-yl)phenyl]-3-(2-fluoro-5-methylphenyl)urea
linifanib	1-[4-(3-amino-1*H*-indazol-4-yl)phényl]-3-(2-fluoro-5-méthylphényl)urée
linifanib	1-[4-(3-amino-1*H*-indazol-4-il)fenil]-3-(2-fluoro-5-metilfenil)urea


$C_{21}H_{18}FN_5O$



lunacalcipolum

lunacalcipol	(1*S*,3*R*,5*Z*,7*E*,23*E*)-24-(2-methylpropane-2-sulfonyl)-9,10-secochola-5,7,10(19),16,23-pentaene-1,3-diol
lunacalcipol	(1*S*,3*R*,5*Z*,7*E*,23*E*)-24-(2-méthylpropane-2-sulfonyl)-9,10-sécochola-5,7,10(19),16,23-pentaène-1,3-diol
lunacalcipol	(1*S*,3*R*,5*Z*,7*E*,23*E*)-24-(2-metilpropano-2-sulfonil)-9,10-secocola-5,7,10(19),16,23-pentaeno-1,3-diol


$C_{28}H_{42}O_4S$



mapracoratum

mapracorat	(2*R*)-1,1,1-trifluoro-4-(5-fluoro-2,3-dihydro-1-benzofuran-7-yl)-4-methyl-2-{[(2-methylquinolin-5-yl)amino]methyl}pentan-2-ol
mapracorat	(2*R*)-1,1,1-trifluoro-4-(5-fluoro-2,3-dihydro-1-benzofuran-7-yl)-4-méthyl-2-{[(2-méthylquinoléin-5-yl)amino]méthyl}pentan-2-ol
mapracorat	(2*R*)-1,1,1-trifluoro-4-(5-fluoro-2,3-dihidro-1-benzofuran-7-il)-4-metil-2-{[(2-metilquinolin-5-il)amino]metil}pentan-2-ol


$C_{25}H_{26}F_4N_2O_2$



marizomibum

marizomib	(1*R*,4*R*,5*S*)-4-(2-chloroethyl)-1-{(*S*)-[(1*S*)-cyclohex-2-en-1-yl](hydroxy)methyl}-5-methyl-6-oxa-2-azabicyclo[3.2.0]heptane-3,7-dione
marizomib	(1*R*,4*R*,5*S*)-4-(2-chloroéthyl)-1-{(*S*)-[(1*S*)-cyclohex-2-én-1-yl](hydroxy)méthyl}-5-méthyl-6-oxa-2-azabicyclo[3.2.0]heptane-3,7-dione
marizomib	(1*R*,4*R*,5*S*)-4-(2-cloroetil)-1-{(*S*)-[(1*S*)-ciclohex-2-en-1-il](hidroxi)metil}-5-metil-6-oxa-2-azabiciclo[3.2.0]heptano-3,7-diona

$C_{15}H_{20}ClNO_4$



mavrilimumabum #

mavrilimumab	immunoglobulin G4-lambda, anti-[*Homo sapiens* CSF2RA (granulocyte-macrophage colony-stimulating factor receptor subunit alpha, GM-CSF-R-alpha, CD116)], *Homo sapiens* monoclonal antibody; gamma4 heavy chain (1-447) [*Homo sapiens* VH (IGHV1-24*01 (93.80%) -(IGHD)-IGHJ3*02) [8.8.13] (1-120) -IGHG4*01 (121-447)], (134-216')-disulfide with lambda light chain (1'-217') [*Homo sapiens* V-LAMBDA (IGLV1-40*01 (87.90%) -IGLJ2*01) [9.3.11] (1'-111') -IGLC2*01 (112'-217')]; (226-226'':229-229'')-bisdisulfide dimer
mavrilimumab	immunoglobuline G4-lambda, anti-[*Homo sapiens* CSF2RA (sous-unité alpha du récepteur du facteur stimulant les colonies de granulocytes et de macrophages, GM-CSF-R-alpha, CD116], *Homo sapiens* anticorps monoclonal; chaîne lourde gamma4 (1-447) [*Homo sapiens* VH (IGHV1-24*01 (93.80%) -(IGHD)-IGHJ3*02) [8.8.13] (1-120) -IGHG4*01 (121-447)], (134-216')-disulfure avec la chaîne légère lambda (1'-217') [*Homo sapiens* V-LAMBDA (IGLV1-40*01 (87.90%) -IGLJ2*01) [9.3.11] (1'-111') -IGLC2*01 (112'-217')]; dimère (226-226'':229-229'')-bisdisulfure
mavrilimumab	inmunoglobulina G4-lambda, anti-[CSF2RA (subunidad alfa del receptor del factor estimulante de colonias de granulocitos y macrófagos, GM-CSF-R-alfa, CD116) de *Homo sapiens*], anticuerpo monoclonal de *Homo sapiens*; cadena pesada gamma4 (1-447) [*Homo sapiens* VH (IGHV1-24*01 (93.80%) -(IGHD)-IGHJ3*02) [8.8.13] (1-120) -IGHG4*01 (121-447)], (134-216')-disulfuro con la cadena ligera lambda (1'-217') [*Homo sapiens* V-LAMBDA (IGLV1-40*01 (87.90%)-IGLJ2*01) [9.3.11] (1'-111') -IGLC2*01 (112'-217')]; dímero (226-226'':229-229'')-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVQSGAE VKKPGASVKV SCKVSGYTLT ELSIHWVRQA PGKGLEWMGG  50
FDPEENEIVY AQRFQGRVTM TEDTSTDTAY MELSSLRSED TAVYYCAIVG 100
SFSPLTLGLW GQGTMVTVSS ASTKGPSVFP LAPCSRSTSE STAALGCLVK 150
DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTKT 200
YTCNVDHKPS NTKVDKRVES KYGPPCPSCP APEFLGGPSV FLFPPKPKDT 250
LMISRTPEVT CVVVDVSQED PEVQFNWYVD GVEVHNAKTK PREEQFNSTY 300
RVVSVLTVLH QDWLNGKEYK CKVSNKGLPS SIEKTISKAK GQPREPQVYT 350
LPPSQEEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS 400
DGSFFLYSRL TVDKSRWQEG NVFSCSVMHE ALHNHYTQKS LSLSLGK    447
```

Light chain / Chaîne légère / Cadena ligera

```
QSVLTQPPSV SGAPGQRVTI SCTGSGSNIG APYDVSWYQQ LPGTAPKLLI  50
YHNNKRPSGV PDRFSGSKSG TSASLAITGL QAEDEADYYC ATVEAGLSGS 100
VFGGGTKLTV LGQPKAAPSV TLFPPSSEEL QANKATLVCL ISDFYPGAVT 150
VAWKADSSPV KAGVETTTPS KQSNNKYAAS SYLSLTPEQW KSHRSYSCQV 200
THEGSTVEKT VAPTECS                                     217
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

```
Intra-H  22-96    147-203   261-321   367-425
         22''-96''  147''-203''  261''-321''  367''-425''
Intra-L  22'-90'   139'-198'
         22'''-90'''  139'''-198'''
Inter-H-L  134-216'  134''-216'''
Inter-H-H  226-226''  229-229''
```

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

297, 297''

moxetumomabum pasudotoxum #

moxetumomab pasudotox	immunoglobulin Fv fragment fused to *Pseudomonas* toxin, anti-[*Homo sapiens* CD22 (sialic acid-binding Ig-like lectin 2, Siglec-2, SIGLEC2, Leu-14, B-lymphocyte cell adhesion molecule, BL-CAM)], *Mus musculus* monoclonal antibody disulfide stabilized Fv fragment with the variable heavy VH domain fused with the truncated form PE38 of *Pseudomonas aeruginosa* exotoxin A (VH-PE38), disulfide linked with the variable kappa domain (V-KAPPA)]; VH-PE38 (1-476) comprising the VH domain (1-123) [methionyl -*Mus musculus* VH [(IGHV5-12-1*01 -(IGHD)-IGHJ3*01) [8.8.16] (2-123)] fused with a 7-mer linker (124-130) and with the *Pseudomonas aeruginosa* exotoxin A (ETA) PE38 fragment (131-476) [277-638 precursor fragment with del 389-405>N (131-476), containing domain II (131-243) with furin proteolytic cleavage site (152-164), domain Ib (244-267), domain III (268-476)], (45-101')-disulfide with V-KAPPA (1'-108') [methionyl -*Mus musculus* V-KAPPA [(IGHKV10-96*01 -IGKJ1*01) [6.3.9] (2'-108')]
moxétumomab pasudotox	fragment Fv d'immunoglobuline fusionné à la toxine de *Pseudomonas*, anti-[*Homo sapiens* CD22 (Ig-like lectine 2 liant l'acide sialique, Siglec-2, SIGLEC2, Leu-14, molécule d'adhésion cellulaire du lymphocyte B, BL-CAM)], *Mus musculus* fragment Fv d'anticorps monoclonal stabilisé par un pont disulfure avec le domaine VH de la chaîne lourde fusionné à la forme tronquée PE38 de l'exotoxine A de *Pseudomonas aeruginosa* (VH-PE38), lié par un pont disulfure au domaine variable kappa (V-KAPPA)]; VH-PE38 (1-476) comprenant le domaine VH (1-123) [méthionyl -*Mus musculus* VH [(IGHV5-12-1*01 -(IGHD)-IGHJ3*01) [8.8.16] (2-123)] fusionné à un 7-mer linker (124-130) et au fragment PE38 de l'exotoxine A de *Pseudomonas aeruginosa* (ETA) (131-476) [fragment précurseur 277-638 avec del 389-405>N (131-476), comprenant domaine II (131-243) dont le site de clivage protéolytique par la furine (152-164), domaine Ib (244-267), domaine III (268-476)], (45-101')- disulfure avec V-KAPPA (1'-108') [méthionyl- *Mus musculus* V-KAPPA (IGHKV10-96*01 -IGKJ1*01) [6.3.9] (2'-108')]
moxetumomab pasudotox	fragmento Fv de inmunoglobulina fusionado con toxina de *Pseudomonas*, anti-[*Homo sapiens* CD22 (lectina de tipo inmunoglobulina 2 que se une al ácido siálico, Siglec-2, SIGLEC2, Leu-14, molécula de adhesión celular del linfocito B, BL-CAM)], *Mus musculus* fragmento Fv de anticuerpo monoclonal estabilizado por un puente disulfuro con el dominio VH de la cadena pesada fusionado a la forma truncada PE38 de la exotoxina A de *Pseudomonas aeruginosa* (VH-PE38), unida por un puente disulfuro al dominio variable kappa (V-KAPPA)]; VH-PE38 (1-476) que comprende el dominio VH (1-123) [metionil -*Mus musculus* VH [(IGHV5-12-1*01 -(IGHD)-IGHJ3*01) [8.8.16] (2-123)] fusionado a un heptámero de unión(124-130) y al fragmento PE38 de la exotoxina A de *Pseudomonas aeruginosa* (ETA) (131-476) [fragmento precursor 277-638 con del 389-405>N (131-476), comprende el dominio II (131-243) con el sitio de ruptura proteolítica por la furina (152-164), dominio Ib (244-267), dominio III (268-476)], (45-101')- disulfuro con V-KAPPA (1'-108') [metionil- *Mus musculus* V-KAPPA (IGHKV10-96*01 -IGKJ1*01) [6.3.9] (2'-108')]

VH-PE38 chain / Chaîne VH-PE38 / Cadena VH-PE38

```
MEVQLVESGG GLVKPGGSLK LSCAASGFAF SIYDMSWVRQ TPEKCLEWVA  50
YISSGGGTTY YPDTVKGRFT ISRDNAKNTL YLQMSSLKSE DTAMYYCARH 100
SGYGTHWGVL FAYWGQGTLV TVSAKASGGP EGGSLAALTA HQACHLPLET 150
FTRHRQPRGW EQLEQCGYPV QRLVALYLAA RLSWNQVDQV IRNALASPGS 200
GGDLGEAIRE QPEQARLALT LAAAESERFV RQGTGNDEAG AANGPADSGD 250
ALLERNYPTG AEFLGDGGDV SFSTRGTQNW TVERLLQAHR QLEERGYVFV 300
GYHGTFLEAA QSIVFGGVRA RSQDLDAIWR GFYIAGDPAL AYGYAQDQEP 350
DARGRIRNGA LLRVYVPRSS LPGFYRTSLT LAAPEAAGEV ERLIGHPLPL 400
RLDAITGPEE EGGRLETILG WPLAERTVVI PSAIPTDPRN VGGDLDPSSI 450
PDKEQAISAL PDYASQPGKP PREDLK                          476
```

V-KAPPA chain / Chaîne V-KAPPA / Cadena V-KAPPA

```
MDIQMTQTTS SLSASLGDRV TISCRASQDI SNYLNWYQQK PDGTVKLLIY  50
YTSILHSGVP SRFSGSGSGT DYSLTISNLE QEDFATYFCQ QGNTLPWTFG 100
CGTKLEIK                                              108
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-H 23-97 144-166
Intra-L 24'-89'
Inter-H-L 45-101'


narlaprevirum

narlaprevir — (1*R*,2*S*,5*S*)-*N*-[(3*S*)-1-(cyclopropylamino)-1,2-dioxoheptan-3-yl]-3-{(2*S*)-3,3-dimethyl-2-[({1-[(2-methylpropane-2-sulfonyl)methyl]cyclohexyl}carbamoyl)amino]butanoyl}-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide

narlaprévir — (1*R*,2*S*,5*S*)-*N*-[(3*S*)-1-(cyclopropylamino)-1,2-dioxoheptan-3-yl]-3-{(2*S*)-3,3-diméthyl-2-[({1-[(2-méthylpropane-2-sulfonyl)méthyl]cyclohexyl}carbamoyl)amino]butanoyl}-6,6-diméthyl-3-azabicyclo[3.1.0]hexane-2-carboxamide

narlaprevir — (1*R*,2*S*,5*S*)-*N*-[(3*S*)-1-(ciclopropilamino)-1,2-dioxoheptan-3-yl]-3-{(2*S*)-3,3-dimetil-2-[({1-[(2-metilpropane-2-sulfonil)metil]ciclohexil}carbamoil)amino]butanoil}-6,6-dimetil-3-azabiciclo[3.1.0]hexane-2-carboxamida

$C_{36}H_{61}N_5O_7S$




omadacyclinum

omadacycline — (4*S*,4a*S*,5a*R*,12a*S*)-4,7-bis(dimethylamino)-9-{[(2,2-dimethylpropyl)amino]methyl}-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide

omadacycline — (4*S*,4a*S*,5a*R*,12a*S*)-4,7-bis(diméthylamino)-9-{[(2,2-diméthylpropyl)amino]méthyl}-3,10,12,12a-tétrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotétracène-2-carboxamide

omadaciclina — (4*S*,4a*S*,5a*R*,12a*S*)-4,7-bis(dimetilamino)-9-{[(2,2-dimetilpropil)amino]metil}-3,10,12,12a-tetrahidroxi-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahidrotetraceno-2-carboxamida


$C_{29}H_{40}N_4O_7$



omecamtivum mecarbilum

omecamtiv mecarbil	methyl 4-[(2-fluoro-3-{[*N*-(6-methylpyridin-3-yl)carbamoyl]amino}phenyl)methyl]piperazine-1-carboxylate
omécamtiv mécarbil	4-[(2-fluoro-3-{[*N*-(6-méthylpyridin-3-yl)carbamoyl]amino}phényl)méthyl]pipérazine-1-carboxylate de méthyle
omecamtiv mecarbilo	4-[(2-fluoro-3-{[*N*-(6-metilpiridin-3-il)carbamoil]amino}fenil)metil]piperazina-1-carboxilato de metilo


$C_{20}H_{24}FN_5O_3$



plinabulinum

plinabulin	(3*Z*,6*Z*)-3-benzylidene-6-{[5-(*tert*-butyl)-1*H*-imidazol-4-yl]methylidene}piperazine-2,5-dione
plinabuline	(3*Z*,6*Z*)-3-benzylidène-6-{[5-(*tert*-butyl)-1*H*-imidazol-4-yl]méthylidène}pipérazine-2,5-dione
plinabulina	(3*Z*,6*Z*)-3-bencilideno-6-{[5-(*terc*-butil)-1*H*-imidazol-4-il]metilideno}piperazina-2,5-diona


$C_{19}H_{20}N_4O_2$



pridopidinum

pridopidine	4-[3-(methanesulfonyl)phenyl]-1-propylpiperidine
pridopidine	4-[3-(méthanesulfonyl)phényl]-1-propylpipéridine
pridopidina	4-[3-(metanosulfonil)fenil]-1-propilpiperidina

$C_{15}H_{23}NO_2S$




raseglurantum

raseglurant 2-[2-(3-fluorophenyl)ethynyl]-4,6-dimethylpyridin-3-amine

raséglurant 2-[2-(3-fluorophényl)éthynyl]-4,6-diméthylpyridin-3-amine

raseglurant 2-[2-(3-fluorofenil)etinil]-4,6-dimetilpiridin-3-amina

$C_{15}H_{13}FN_3$




remimazolamum

remimazolam methyl 3-{(4*S*)-8-bromo-1-methyl-6-(pyridin-2-yl)-4*H*-imidazo[1,2-*a*][1,4]benzodiazepin-4-yl}propanoate

rémimazolam 3-{(4*S*)-8-bromo-1-méthyl-6-(pyridin-2-yl)-4*H*-imidazo[1,2-*a*][1,4]benzodiazépin-4-yl}propanoate de méthyle

remimazolam 3-{(4*S*)-8-bromo-1-metil-6-(piridin-2-il)-4*H*-imidazo[1,2-*a*][1,4]benzodiazepin-4-il}propanoato de metilo

$C_{21}H_{19}BrN_4O_2$




resminostatum

resminostat (2*E*)-3-[1-({4-[(dimethylamino)methyl]phenyl}sulfonyl)-1*H*-pyrrol-3-yl]-*N*-hydroxyprop-2-enamide

resminostat (2*E*)-3-[1-({4-[(diméthylamino)méthyl]phényl}sulfonyl)-1*H*-pyrrol-3-yl]-*N*-hydroxyprop-2-énamide

resminostat (2*E*)-3-[1-({4-[(dimetilamino)metil]fenil}sulfonil)-1*H*-pirrol-3-il]-*N*-hidroxiprop-2-enamida

$C_{16}H_{19}N_3O_4S$




revamilastum

revamilast — 3,5-dichloro-4-{[6-(difluoromethoxy)[1]benzofuro[3,2-*c*]pyridine-9-yl]carboxamido}pyridine 1-oxide

révamilast — 1-oxyde de 3,5-dichloro-4-{[6-(difluorométhoxy)[1]benzofuro[3,2-*c*]pyridine-9-yl]carboxamido}pyridine

revamilast — 1-óxido de 3,5-dicloro-4-[6-(difluorometoxi)[1]benzofuro[3,2-*c*]piridina-9-carboxamido]piridina

$C_{18}H_9Cl_2F_2N_3O_4$




rintatolimodum

rintatolimod — poly[5')-inosinylyl-(3'→] duplex with poly[dodecakis[3')-cytidylyl-(5'→]3')-uridylyl-(5'→]

rintatolimod — poly[5')-inosinylyl-(3'→] duplex avec poly[dodécakis[3')-cytidylyl-(5'→]3')-uridylyl-(5'→]

rintatolimod — poli[5')-inosinilil-(3'→] dúplex con poli[dodecakis[3')-citidilil-(5'→]3')-uridilil-(5'→]

$[[C_{10}H_{11}N_4O_7P]_{13}]_n \cdot [[C_9H_{12}N_3O_7P]_{12}[C_9H_{11}N_2O_8P]]_n$



secukinumabum #

secukinumab — immunoglobulin G1-kappa, anti-[*Homo sapiens* interleukin 17A (IL17A, IL-17A)], *Homo sapiens* monoclonal antibody; gamma1 heavy chain (1-457) [*Homo sapiens* VH (IGHV3-7*01 (92.90%) -(IGHD)-IGHJ2*01) [8.8.20] (1-127) -IGHG1*03 (128-457)], (230-215')-disulfide with kappa light chain (1'-215') [*Homo sapiens* V-KAPPA (IGKV3-20*01 (100.00%) -IGKJ2*02) [7.3.9] (1'-108') -IGKC*01 (109'-215')]; (269-236":239-239")-bisdisulfide dimer

sécukinumab — immunoglobuline G1-kappa, anti-[*Homo sapiens* interleukine 17A (IL17A, IL-17A)], *Homo sapiens* anticorps monoclonal; chaîne lourde gamma1 (1-457) [*Homo sapiens* VH (IGHV3-7*01 (92.90%) -(IGHD)-IGHJ2*01) [8.8.20] (1-127) -IGHG1*03 (128-457)], (230-215')-disulfure avec la chaîne légère kappa (1'-215') [*Homo sapiens* V-KAPPA (IGKV3-20*01 (100.00%) -IGKJ2*01) [7.3.9] (1'-108') -IGKC*01 (109'-215')]; dimère (236-236":239-239")-bisdisulfure

secukinumab

inmunoglobulina G1-kappa, anti-[*Homo sapiens* IL17A (interleukina 17A, IL-17A)], anticuerpo monoclonal *de Homo sapiens*;
cadena pesada gamma1 (1-457) [*Homo sapiens* VH (IGHV3-7*01 (92.90%) -(IGHD)-IGHJ2*01) [8.8.20] (1-127) -IGHG1*03 (128-457)], (230-215')-disulfuro con la cadena ligera kappa (1'-215') [*Homo sapiens* V-KAPPA (IGKV3-20*01 (100.00%) -IGKJ2*01) [7.3.9] (1'-108') -IGKC*01 (109'-215')]; dímero bisdisulfuro-(236-236'':239-239'')

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVESGGG LVQPGGSLRL SCAASGFTFS NYWMNWVRQA PGKGLEWVAA  50
INQDGSEKYY VGSVKGRFTI SRDNAKNSLY LQMNSLRVED TAVYYCVRDY 100
YDILTDYYIH YWYFDLWGRG TLVTVSSAST KGPSVFPLAP SSKSTSGGTA 150
ALGCLVKDYF PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS 200
SSLGTQTYIC NVNHKPSNTK VDKRVEPKSC DKTHTCPPCP APELLGGPSV 250
FLFPPKPKDT LMISRTPEVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK 300
PREEQYNSTY RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK 350
GQPREPQVYT LPPSREEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN 400
YKTTPPVLDS DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS 450
LSLSPGK                                               457
```

Light chain / Chaîne légère / Cadena ligera

```
EIVLTQSPGT LSLSPGERAT LSCRASQSVS SSYLAWYQQK PGQAPRLLIY  50
GASSRATGIP DRFSGSGSGT DFTLTISRLE PEDFAVYYCQ QYGSSPCTFG 100
QGTRLEIKRT VAAPSVFIFP PSDEQLKSGT ASVVCLLNNF YPREAKVQWK 150
VDNALQSGNS QESVTEQDSK DSTYSLSSTL TLSKADYEKH KVYACEVTHQ 200
GLSSPVTKSF NRGEC                                      215
```

Disulfide bridges location / Position des ponts disulfure /Posiciones de los puentes disulfuro

Intra-H 22-96 154-210 271-331 377-435
22''-96'' 154''-210'' 271''-331'' 377''-435''
Intra-L 23'-89' 135'-195'
23'''-89''' 135'''-195'''
Inter-H-L 230-215' 230''-215'''
Inter-H-H 236-236'' 239-239''

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
307, 307''

selexipagum

selexipag

2-{4-[(5,6-diphenylpyrazin-2-yl)(propan-2-yl)amino]butoxy}-*N*-(methanesulfonyl)acetamide


sélexipag

2-{4-[(5,6-diphénylpyrazin-2-yl)(propan-2-yl)amino]butoxy}-*N*-(méthanesulfonyl)acétamide

selexipag

2-{4-[(5,6-difenilpirazin-2-il)(propan-2-il)amino]butoxi}-*N*-(metanosulfonil)acetamida

$C_{26}H_{32}N_4O_4S$



sotaterceptum #

sotatercept

fusion protein for immune applications (FPIA) comprising ACVR2A (activin receptor type 2A, activin receptor type IIA) fragment fused with immunoglobulin G1 Fc fragment, and binding activin, a member of the TGF beta family;
ACVR2A, 21-135 precursor fragment (1-115) -threonyl-triglycyl linker (116-119) -gamma1 chain H-CH2-CH3 fragment (120-344) [*Homo sapiens* IGHG1*03 hinge (120-127), CH2, A115>V (128-237), CH3 (238-344)]; (123-123':126-126')-bisdisulfide dimer

sotatercept

protéine de fusion pour applications immunitaires (FPIA) comprenant un fragment d'ACVR2A (récepteur type 2A de l'activine, récepteur type IIA de l'activine) fusionné au fragment Fc de l'immunoglobuline G1, et liant l'activine, un membre de la famille du TGF bêta;
fragment précurseur 21-135 de ACVR2A (1-115) -linker thréonyl-triglycyl (116-119) -fragment H-CH2-CH3 de chaîne gamma1 (120-344) [*Homo sapiens* IGHG1*03 charnière (120-127), CH2, A115>V (128-237), CH3 (238-344)]; dimère (123-123':126-126')-bisdisulfure

sotatercept

proteína de fusión para aplicaciones inmunitarias (FPIA) que comprende un fragmento de ACVR2A (receptor tipo 2A de la activina, receptor tipo IIA de la activina) fusionado al fragmento Fc de la inmunoglobulina G1, y que capta la activina, un miembro de la familia del TGF beta;
fragmento precursor 21-135 de ACVR2A (1-115)-conector treonil-triglicil (116-119) -fragmento H-CH2-CH3 de cadena gamma1 (120-344) [*Homo sapiens* IGHG1*03 bisagra(120-127), CH2, A115>V (128-237), CH3 (238-344)]; dímero (123-123':126-126')-bisdisulfuro

$C_{3448}H_{5264}N_{920}O_{1058}S_{42}$

Fused chain / chaine fusionnée / cadena fusionada

```
ILGRSETQEC LFFNANWEKD RTNQTGVEPC YGDKDKRRHC FATWKNISGS  50
IEIVKQGCWL DDINCYDRTD CVEKKDSPEV YFCCCEGNMC NEKFSYFPEM 100
EVTQPTSNPV TPKPPTGGGT HTCPPCPAPE LLGGPSVFLF PPKPKDTLMI 150
SRTPEVTCVV VDVSHEDPEV KFNWYVDGVE VHNAKTKPRE EQYNSTYRVV 200
SVLTVLHQDW LNGKEYKCKV SNKALPVPIE KTISKAKGQP REPQVYTLPP 250
SREEMTKNQV SLTCLVKGFY PSDIAVEWES NGQPENNYKT TPPVLDSDGS 300
FFLYSKLTVD KSRWQQGNVF SCSVMHEALH NHYTQKSLSL SPGK       344
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

```
Intra-chain  10-40  30-58    65-84   71-83   85-90    158-218  264-322
            10'-40' 30'-58' 65'-84' 71'-83' 85'-90' 158'-218' 264'-322'
Inter-chains 123-123' 126-126'
```

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
23, 46, 194, 23', 46', 194'

suvizumabum #

suvizumab

immunoglobulin G1-kappa, anti-[human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein gp120 third variable loop V3], humanized monoclonal antibody;
gamma1 heavy chain (1-448) [humanized VH (*Homo sapiens* IGHV1-46*01 (77.60%) -(IGHD)-IGHJ4*01) [8.8.11] (1-118) -*Homo sapiens* IGHG1*01 (119-448)], (221-220')-disulfide with kappa light chain (1'-220') [humanized V-KAPPA (*Homo sapiens* IGKV4-1*01 (77.20%) -IGKJ1*01) [12.3.9] (1'-113') -*Homo sapiens* IGKC*01 (114'-220')]; (227-227":230-230")-bisdisulfide dimer

suvizumab

immunoglobuline G1-kappa, anti-[troisième boucle variable V3 de la glycoprotéine d'enveloppe gp120 du virus type 1 de l'immunodéficience humaine (VIH-1)], anticorps monoclonal humanisé;
chaîne lourde gamma1 (1-448) [VH humanisé (*Homo sapiens* IGHV1-46*01 (77.60%) -(IGHD)-IGHJ4*01) [8.8.11] (1-118) -*Homo sapiens* IGHG1*01 (119-448)], (221-220')-disulfure avec la chaîne légère kappa (1'-220') [V-KAPPA humanisé (*Homo sapiens* IGKV4-1*01 (77.20%) -IGKJ1*01) [12.3.9] (1'-113') -*Homo sapiens* IGKC*01 (114'-220')]; dimère (227-227":230-230")-bisdisulfure

suvizumab

inmunoglobulina G1-kappa, anti-[tercer bucle variable V3 de la glicoproteína de la envoltura gp120 del virus tipo 1 de la inmunodeficiencia humana (VIH-1)], anticuerpo monoclonal humanizado;
cadena pesada gamma1 (1-448) [VH humanizado(*Homo sapiens* IGHV1-46*01 (77.60%) -(IGHD)-IGHJ4*01) [8.8.11] (1-118) -*Homo sapiens* IGHG1*01 (119-448)], (221-220')-disulfuro con la cadena ligera kappa (1'-220') [V-KAPPA humanizada (*Homo sapiens* IGKV4-1*01 (77.20%) -IGKJ1*01) [12.3.9] (1'-113') -*Homo sapiens* IGKC*01 (114'-220')]; dímero bisdisulfuro-(227-227":230-230")

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVQSGAE VKKPGASVKV SCKASGYTFT NSWIGWFRQA PGQGLEWIGD  50
IYPGGGYTNY NEIFKGKATM TADTSTNTAY MELSSLRSED TAVYYCSRGI 100
PGYAMDYWGQ GTLVTVSSAS TKGPSVFPLA PSSKSTSGGT AALGCLVKDY 150
FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSSLGTQTYI 200
CNVNHKPSNT KVDKKVEPKS CDKTHTCPPC PAPELLGGPS VFLFPPKPKD 250
TLMISRTPEV TCVVVDVSHE DPEVKFNWYV DGVEVHNAKT KPREEQYNST 300
YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY 350
TLPPSRDELT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD 400
SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH EALHNHYTQK SLSLSPGK   448
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQRPDS LSASVGDRVT MSCKSSQSLL NSGDQKNYLT WYQQKPGQPP  50
KLLIYWASTG ESGVPDRFSG SGSGTDFTFT ISSLQPEDIA TYYCQNDYSY 100
PWTFGQGTKV EIKRTVAAPS VFIFPPSDEQ LKSGTASVVC LLNNFYPREA 150
KVQWKVDNAL QSGNSQESVT EQDSKDSTYS LSSTLTLSKA DYEKHKVYAC 200
EVTHQGLSSP VTKSFNRGEC                                   220
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

```
Intra-H  21-96    145-201   262-322   368-426
         21"-96"  145"-201" 262"-322" 368"-426"
Intra-L  23'-94'   140'-200'
         23'"-94'" 140'"-200'"
Inter-H-L 221-220' 221"-220'"
Inter-H-H 227-227" 230-230"
```

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
298, 298"

tafoxiparinum natricum

tafoxiparin sodium

sodium salt of a low molecular mass heparin that is obtained by periodate oxidative depolymerization of heparin from porcine intestinal mucosa followed alkaline β-elimination and reduction of the products; the majority of the components have a 2-deoxy-6-*O*-sulfo-2-(sulfoamino)-α-D-glucopyranosyl structure at the non-reducing end and a (hydroxymethyl)allyl 2-deoxy-6-*O*-sulfo-2-(sulfoamino)-α-D-glucopyranoside structure at the reducing end of their chain; the average molecular mass is approximately 6000 Daltons and 80% of the components ranging between 2000 and 10000 Daltons; the degree of sulfatation is of 2 to 2.5 per disaccharidic unit

tafoxiparine sodique


sel de sodium d'héparine de basse masse moléculaire obtenue par dépolymérisation oxydative, à l'aide de periodate, d'héparine de muqueuse intestinale de porc, suivie d'une β-élimination alcaline puis d'une réduction des produits. La majorité des composants présentent une structure 2-déoxy-6-*O*-sulfo-2-(sulfoamino)-α-D-glucopyranosyle à l'extrémité non réductrice et une structure 2-déoxy-6-*O*-sulfo-2-(sulfoamino)-α-D-glucopyranoside de (hydroxyméthyl)allyle à l'extrémité réductrice de leur chaîne; les masses moléculaires relatives des constituants ont une moyenne voisine de 6000 Daltons et celles de 80% des constituants sont comprises entre 2000 et 10000; le degré de sulfatation est compris entre 2 et 2,5 par unité disaccharide

tafoxiparina sódica	sal sódica de la heparina de baja masa molecular obtenida de mucosa intestinal de cerdo por despolimerización oxidativa mediante un proceso controlado en el que se utiliza periodato, siguido de una β-eliminación alcalina y de una reducción de los productos. La mayoría de los componentes presentan la estructura 2-desoxi-6-*O*-sulfo-2-(sulfoamino)-α-D-glucopiranosilo en el extremo no reductor y la estructura 2-desoxi-6-*O*-sulfo-2-(sulfoamino)-α-D-glucopiranosido de (hidroximetilo)alilo en el extremo reductor de su cadena ; la masa molecular relativa media es de aproximadamente 6000 daltons y la masa molecular relativa media de 80 % de los componentes está comprendida entre 2000 y 10000, el grado de sulfatación oscila entre 2 y 2,5 por unidad de disacárido

tenifatecanum

tenifatecan	(4*S*)-4,11-diethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1*H*-pyrano[3',4':6,7]indolizino[1,2-*b*]quinolin-9-yl (2*R*)-2,5,7,8-tetramethyl-2-[(4*R*,8*R*)-4,8,12-trimethyltridecyl]-3,4-dihydro-2*H*-chromen-6-yl butanedioate
ténifatécan	butanedioate de (4*S*)-4,11-diéthyl-4-hydroxy-3,14-dioxo-3,4,12,14-tétrahydro-1*H*-pyrano[3',4':6,7]indolizino[1,2-*b*]quinoléin-9-yle et de (2*R*)-2,5,7,8-tétraméthyl-2-[(4*R*,8*R*)-4,8,12-triméthyltridécyl]-3,4-dihydro-2*H*-chromén-6-yle
tenifatecán	butanodioato de (4*S*)-4,11-dietil-4-hidroxi-3,14-dioxo-3,4,12,14-tetrahidro-1*H*-pirano[3',4':6,7]indolizino[1,2-*b*]quinolin-9-ilo y (2*R*)-2,5,7,8-tetrametil-2-[(4*R*,8*R*)-4,8,12-trimetiltridecil]-3,4-dihidro-2*H*-cromen-6-ilo


$C_{55}H_{72}N_2O_9$



tideglusibum

tideglusib	4-benzyl-2-(naphthalen-1-yl)-1,2,4-thiadiazolidine-3,5-dione
tidéglusib	4-benzyl-2-(naphtalén-1-yl)-1,2,4-thiadiazolidine-3,5-dione
tideglusib	4-bencil-2-(naftalen-1-il)-1,2,4-tiadiazolidina-3,5-diona

$C_{19}H_{14}N_2SO_2$




tivozanibum

tivozanib — 1-{2-chloro-4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-3-(5-methyl-1,2-oxazol-3-yl)urea

tivozanib — 1-{2-chloro-4-[(6,7-diméthoxyquinoléin-4-yl)oxy]phényl}-3-(5-méthyl-1,2-oxazol-3-yl)urée

tivozanib — 1-{2-cloro-4-[(6,7-dimetoxiquinolin-4-il)oxi]fenil}-3-(5-metil-1,2-oxazol-3-il)urea

$C_{22}H_{19}ClN_4O_5$




tonapofyllinum

tonapofylline — 3-{4-[2,6-dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1*H*-purin-8-yl]bicyclo[2.2.2]octan-1-yl}propanoic acid

tonapofylline — acide 3-{4-[2,6-dioxo-1,3-dipropyl-2,3,6,7-tétrahydro-1*H*-purin-8-yl]bicyclo[2.2.2]octan-1-yl}propanoïque

tonapofilina — ácido 3-{4-[2,6-dioxo-1,3-dipropil-2,3,6,7-tetrahidro-1*H*-purin-8-il]biciclo[2.2.2]octan-1-il}propanoico

$C_{22}H_{32}N_4O_4$




topiroxostatum

topiroxostat — 4-[5-(pyridin-4-yl)-1*H*-1,2,4-triazol-3-yl]pyridine-2-carbonitrile

topiroxostat — 4-[5-(pyridin-4-yl)-1*H*-1,2,4-triazol-3-yl]pyridine-2-carbonitrile

topiroxostat — 4-[5-(piridin-4-il)-1*H*-1,2,4-triazol-3-il]piridina-2-carbonitrilo

$C_{13}H_8N_6$



tralokinumabum #

tralokinumab — immunoglobulin G4-lambda, anti-[*Homo sapiens* IL13 (interleukin 13, IL-13)], *Homo sapiens* monoclonal antibody;
gamma4 heavy chain (1-449) [*Homo sapiens* VH (IGHV1-18*01 (92.90%) -(IGHD)-IGHJ2*01) [8.8.15] (1-122) -IGHG4*01 (123-449)], (136-213')-disulfide with lambda light chain (1'-214') [*Homo sapiens* V-LAMBDA (IGLV3-21*03 (93.70%) -IGLJ2*01) [6.3.11] (1'-108') -IGLC2*01 (109'-214')]; (228-228'':231-231'')-bisdisulfide dimer

tralokinumab — immunoglobuline G4-lambda, anti-[*Homo sapiens* IL13 (interleukine 13, IL-13)], *Homo sapiens* anticorps monoclonal;
chaîne lourde gamma4 (1-449) [*Homo sapiens* VH (IGHV1-18*01 (92.90%) -(IGHD)-IGHJ2*01) [8.8.15] (1-122) -IGHG4*01(123-449)], (136-213')-disulfure avec la chaîne légère lambda (1'-214') [*Homo sapiens* V-LAMBDA (IGLV3-21*03 (93.70%) -IGLJ2*01) [6.3.11] (1'-108') -IGLC2*01 (109'-214')]; dimère (228-228'':231-231'')-bisdisulfure

tralokinumab — inmunoglobulina G4-lambda, anti-[IL13 (interleukina 13, IL-13) de *Homo sapiens*], anticuerpo monoclonal de *Homo sapiens*;
cadena pesada gamma4 (1-449) [*Homo sapiens* VH (IGHV1-18*01 (92.90%) -(IGHD)-IGHJ2*01) [8.8.15] (1-122) -IGHG4*01(123-449)], (136-213')-disulfuro con la cadena ligera lambda (1'-214') [*Homo sapiens* V-LAMBDA (IGLV3-21*03 (93.70%) -IGLJ2*01) [6.3.11] (1'-108') -IGLC2*01 (109'-214')]; dímero (228-228'':231-231'')-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVQSGAE VKKPGASVKV SCKASGYTFT NYGLSWVRQA PGQGLEWMGW  50
ISANNGDTNY GQEFQGRVTM TTDTSTSTAY MELRSLRSDD TAVYYCARDS 100
SSSWARWFFD LWGRGTLVTV SSASTKGPSV FPLAPCSRST SESTAALGCL 150
VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ SSGLYSLSSV VTVPSSSLGT 200
KTYTCNVDHK PSNTKVDKRV ESKYGPPCPS CPAPEFLGGP SVFLFPPKPK 250
DTLMISRTPE VTCVVVDVSQ EDPEVQFNWY VDGVEVHNAK TKPREEQFNS 300
TYRVVSVLTV LHQDWLNGKE YKCKVSNKGL PSSIEKTISK AKGQPREPQV 350
YTLPPSQEEM TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL 400
DSDGSFFLYS RLTVDKSRWQ EGNVFSCSVM HEALHNHYTQ KSLSLSLGK  449
```

Light chain / Chaîne légère / Cadena ligera

```
SYVLTQPPSV SVAPGKTARI TCGGNIIGSK LVHWYQQKPG QAPVLVIYDD  50
GDRPSGIPER FSGSNSGNTA TLTISRVEAG DEADYYCQVW DTGSDPVVFG 100
GGTKLTVLGQ PKAAPSVTLF PPSSEELQAN KATLVCLISD FYPGAVTVAW 150
KADSSPVKAG VETTTPSKQS NNKYAASSYL SLTPEQWKSH RSYSCQVTHE 200
GSTVEKTVAP TECS                                        214
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

```
Intra-H   22-96     149-205    263-323     369-427
          22''-96''  149''-205''  263''-323''  369''-427''
Intra-L   22'-87'     136'-195'
          22'''-87'''  136'''-195'''
Inter-H-L  136-213'  136''-213'''
Inter-H-H  228-228''  231-231''
```

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
299, 299''


varlitinibum

varlitinib — N^4-{3-chloro-4-[(1,3-thiazol-2-yl)methoxy]phenyl}-N^6-[(4*R*)-4-methyl-4,5-dihydro-1,3-oxazol-2-yl]quinazoline-4,6-diamine

varlitinib — N^4-{3-chloro-4-[(1,3-thiazol-2-yl)méthoxy]phényl}-N^6-[(4*R*)-4-méthyl-4,5-dihydro-1,3-oxazol-2-yl]quinazoline-4,6-diamine

varlitinib — N^4-{3-cloro-4-[(1,3-tiazol-2-il)metoxi]fenil}-N^6-[(4*R*)-4-metil-4,5-dihidro-1,3-oxazol-2-il]quinazolina-4,6-diamina

$C_{22}H_{19}ClN_6O_2S$




veliparibum

veliparib — 2-[(2*R*)-2-methylpyrrolidin-2-yl]-1*H*-benzimidazole-4-carboxamide

véliparib — 2-[(2*R*)-2-méthylpyrrolidin-2-yl]-1*H*-benzimidazole-4-carboxamide

veliparib — 2-[(2*R*)-2-metilpirrolidin-2-il]-1*H*-benzoimidazol-4-carboxamida

$C_{13}H_{16}N_4O$




verucerfontum

verucerfont — 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-*N*-[(1*S*)-1-(3-methyl-1,2,4-oxadiazol-5-yl)propyl]pyrazolo[1,5-*a*]pyrimidin-7-amine

vérucerfont — 3-(4-méthoxy-2-méthylphényl)-2,5-diméthyl-*N*-[(1*S*)-1-(3-méthyl-1,2,4-oxadiazol-5-yl)propyl]pyrazolo[1,5-*a*]pyrimidin-7-amine

verucerfont — 2,5-dimetil-3-(2-metilfenil-4-metoxi)-*N*-[(1*S*)-1-(3-metil-1,2,4-oxadiazol-5-il)propil]pirazolo[1,5-*a*]pirimidin-7-amina

$C_{22}H_{26}N_6O_2$




volasertibum

volasertib — *N*-{*trans*-4-[4-(cyclopropylmethyl)piperazin-1-yl]cyclohexyl}-4-{[(7*R*)-7-ethyl-5-methyl-6-oxo-8-(propan-2-yl)-5,6,7,8-tetrahydropteridin-2-yl]amino}-3-methoxybenzamide

volasertib — *N*-{*trans*-4-[4-(cyclopropylméthyl)pipérazin-1-yl]cyclohexyl}-4-{[(7*R*)-7-éthyl-5-méthyl-6-oxo-8-(propan-2-yl)-5,6,7,8-tétrahydroptéridin-2-yl]amino}-3-méthoxybenzamide

volasertib — *N*-{*trans*-4-[4-(ciclopropilmetil)piperazin-1-il]ciclohexil}-4-{[(7*R*)-7-etil-5-metil-6-oxo-8-(propan-2-il)-5,6,7,8-tetrahidropteridin-2-il]amino}-3-metoxibenzamida

$C_{34}H_{50}N_8O_3$



vonicogum alfa #

vonicog alfa — [618-threonine,709-aspartic acid]von Willebrand factor *Homo sapiens* (1381A>T,1472H>D variant)

vonicog alfa — [618-thréonine,709-acide aspartique]facteur de von Willebrand *Homo sapiens* (variant 1381A>T,1472H>D)

vonicog alfa — [618-treonina,709-ácido aspatico]factor de von Willebrand *Homo sapiens* (variante 1381A>T,1472H>D)

$C_{9712}H_{15373}N_{2737}O_{3032}S_{210}$

```
SLSCRPPMVK LVCPADNLRA EGLECTKTCQ NYDLECMSMG CVSGCLCPPG   50
MVRHENRCVA LERCPCFHQG KEYAPGETVK IGCNTCVCRD RKWNCTDHVC  100
DATCSTIGMA HYLTFDGLKY LFPGECQYVL VQDYCGSNPG TFRILVGNKG  150
CSHPSVKCKK RVTILVEGGE IELFDGEVNV KRPMKDETHF EVVESGRYII  200
LLLGKALSVV WDRHLSISVV LKQTYQEKVC GLCGNFDGIQ NNDLTSSNLQ  250
VEEDPVDFGN SWKVSSQCAD TRKVPLDSSP ATCHNNIMKQ TMVDSSCRIL  300
TSDVFQDCNK LVDPEPYLDV CIYDTCSCES IGDCACFCDT IAAYAHVCAQ  350
HGKVVTWRTA TLCPQSCEER NLRENGYECE WRYNSCAPAC QVTCQHPEPL  400
ACPVQCVEGC HAHCPPGKIL DELLQTCVDP EDCPVCEVAG RRFASGKKVT  450
LNPSDPEHCQ ICHCDVVNLT CEACQEPGGL VVPPTDAPVS PTTLYVEDIS  500
EPPLHDFYCS RLLDLVFLLD GSSRLSEAEF EVLKAFVVDM MERLRISQKW  550
VRVAVVEYHD GSHAYIGLKD RKRPSELRRI ASQVKYAGSQ VASTSEVLKY  600
TLFQIFSKID RPEASRITLL LMASQEPQRM SRNFVRYVQG LKKKKVIVIP  650
VGIGPHANLK QIRLIEKQAP ENKAFVLSSV DELEQQRDEI VSYLCDLAPE  700
APPPTLPPDM AQVTVGPGLL GVSTLGPKRN SMVLDVAFVL EGSDKIGEAD  750
FNRSKEFMEE VIQRMDVGQD SIHVTVLQYS YMVTVEYPFS EAQSKGDILQ  800
RVREIRYQGG NRTNTGLALR YLSDHSFLVS QGDREQAPNL VYMVTGNPAS  850
DEIKRLPGDI QVVPIGVGPN ANVQELERIG WPNAPILIQD FETLPREAPD  900
LVLQRCCSGE GLQIPTLSPA PDCSQPLDVI LLLDGSSSFP ASYFDEMKSF  950
AKAFISKANI GPRLTQVSVL QYGSITTIDV PWNVVPEKAH LLSLVDVMQR 1000
EGGPSQIGDA LGFAVRYLTS EMHGARPGAS KAVVILVTDV SVDSVDAAAD 1050
AARSNRVTVF PIGIGDRYDA AQLRILAGPA GDSNVVKLQR IEDLPTMVTL 1100
GNSFLHKLCS GFVRICMDED GNEKRPGDVW TLPDQCHTVT CQPDGQTLLK 1150
SHRVNCDRGL RPSCPNSQSP VKVEETCGCR WTCPCVCTGS STRHIVTFDG 1200
QNFKLTGSCS YVLFQNKEQD LEVILHNGAC SPGARQGCMK SIEVKHSALS 1250
VELHSDMEVT VNGRLVSVPY VGGNMEVNVY GAIMHEVRFN HLGHIFTFTP 1300
QNNEFQLQLS PKTFASKTYG LCGICDENGA NDFMLRDGTV TTDWKTLVQE 1350
WTVQRPGQTC QPILEEQCLV PDSSHCQVLL LPLFAECHKV LAPATFYAIC 1400
QQDSCHQEQV CEVIASYAHL CRTNGVCVDW RTPDFCAMSC PPSLVYNHCE 1450
HGCPRHCDGN VSSCGDHPSE GCFCPPDKVM LEGSCVPEEA CTQCIGEDGV 1500
QHQFLEAWVP DHQPCQICTC LSGRKVNCTT QPCPTAKAPT CGLCEVARLR 1550
QNADQCCPEY ECVCDPVSCD LPPVPHCERG LQPTLTNPGE CRPNFTCACR 1600
KEECKRVSPP SCPPHRLPTL RKTQCCDEYE CACNCVNSTV SCPLGYLAST 1650
ATNDCGCTTT TCLPDKVCVH RSTIYPVGQF WEEGCDVCTC TDMEDAVMGL 1700
RVAQCSQKPC EDSCRSGFTY VLHEGECCGR CLPSACEVVT GSPRGDSQSS 1750
WKSVGSQWAS PENPCLINEC VRVKEEVFIQ QRNVSCPQLE VPVCPSGFQL 1800
SCKTSACCPS CRCERMEACM LNGTVIGPGK TVMIDVCTTC RCMVQVGVIS 1850
GFKLECRKTT CNPCPLGYKE ENNTGECCGR CLPTACTIQL RGGQIMTLKR 1900
DETLQDGCDT HFCKVNERGE YFWEKRVTGC PPFDEHKCLA EGGKIMKIPG 1950
TCCDTCEEPE CNDITARLQY VKVGSCKSEV EVDIHYCQGK CASKAMYSID 2000
INDVQDQCSC CSPTRTEPMQ VALHCTNGSV VYHEVLNAME CKCSPRKCSK 2050
```

yttrium (^{90}Y) clivatuzumabum tetraxetanum #

yttrium (^{90}Y) clivatuzumab tetraxetan	immunoglobulin G1-kappa, anti-[*Homo sapiens* MUC1 (mucin 1, polymorphic epithelial mucin, PEM, CD227)], humanized monoclonal antibody, yttrium (^{90}Y) radiolabelled tetraxetan conjugate; gamma1 heavy chain (1-449) [humanized VH (*Homo sapiens* IGHV1-2*02 (79.60%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -*Homo sapiens* IGHG1*03 (120-449)], (222-215')-disulfide with kappa light chain (1'-215') [humanized V-KAPPA (*Homo sapiens* IGKV1-13*02 (78.90%) -IGKJ2*01) [7.3.9] (1'-108') -*Homo sapiens* IGKC*01 (109'-215')]; (228-228":231-231")-bisdisulfide dimer; yttrium (^{90}Y) radiolabelled tetraxetan (DOTA) conjugate
yttrium (^{90}Y) clivatuzumab tétraxétan	immunoglobuline G1-kappa, anti-[*Homo sapiens* MUC1 (mucine 1, mucine épithéliale polymorphique, PEM, CD227)], anticorps monoclonal humanisé, conjugué au tétraxétan et radiomarqué à l'yttrium (^{90}Y); chaîne lourde gamma1 (1-449) [VH humanisé (*Homo sapiens* IGHV1-2*02 (79.60%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -*Homo sapiens* IGHG1*03 (120-449)], (222-215')-disulfure avec la chaîne légère kappa (1'-215') [V-KAPPA humanisé (*Homo sapiens* IGKV1-13*02 (78.90%) -IGKJ2*01) [7.3.9] (1'-108') -*Homo sapiens* IGKC*01 (109'-215')]; dimère (228-228":231-231")-bisdisulfure; conjugué au tétraxetan (DOTA) et radiomarqué à l'yttrium (^{90}Y)
ytrio (^{90}Y) clivatuzumab tetraxetán	inmunoglobulina G1-kappa, anti-[*Homo sapiens* MUC1 (mucina 1, mucina epitelial polimórfica, PEM, CD227)], anticuerpo monoclonal humanizado, conjugado al tetraxetano y radiomarcado con ytrio (^{90}Y); cadena pesada gamma1 (1-449) [VH humanizada (*Homo sapiens* IGHV1-2*02 (79.60%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -*Homo sapiens* IGHG1*03 (120-449)], (222-215')-disulfuro con la cadena ligera kappa (1'-215') [V-KAPPA humanizada (*Homo sapiens* IGKV1-13*02 (78.90%) -IGKJ2*01) [7.3.9] (1'-108') -*Homo sapiens* IGKC*01 (109'-215')]; dimero (228-228":231-231")-bisdisulfuro; conjugada al tetraxetano (DOTA) y radiomarcado con ytrio (^{90}Y)

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLQQSGAE VKKPGASVKV SCEASGYTFP SYVLHWVKQA PGQGLEWIGY  50
INPYNDGTQY NEKFKGKATL TRDTSINTAY MELSRLRSDD TAVYYCARGF 100
GGSYGFAYWG QGTLVTVSSA STKGPSVFPL APSSKSTSGG TAALGCLVKD 150
YFPEPVTVSW NSGALTSGVH TFPAVLQSSG LYSLSSVVTV PSSSLGTQTY 200
ICNVNHKPSN TKVDKRVEPK SCDKTHTCPP CPAPELLGGP SVFLFPPKPK 250
DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS 300
TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV 350
YTLPPSREEM TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL 400
DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM HEALHNHYTQ KSLSLSPGK  449
```

Light chain / Chaîne légère / Cadena ligera


```
DIQLTQSPSS LSASVGDRVT MTCSASSSVS SSYLYWYQQK PGKAPKLWIY  50
STSNLASGVP ARFSGSGSGT DFTLTISSLQ PEDSASYFCH QWNRYPYTFG 100
GGTRLEIKRT VAAPSVFIFP PSDEQLKSGT ASVVCLLNNF YPREAKVQWK 150
VDNALQSGNS QESVTEQDSK DSTYSLSSTL TLSKADYEKH KVYACEVTHQ 200
GLSSPVTKSF NRGEC                                       215
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H 22-96 146-202 263-323 369-427
22"-96" 146"-202" 263"-323" 369"-427"
Intra-L 23'-89' 135'-195'
23'"-89'" 135'"-195'"
Inter-H-L 222-215' 222"-215'"
Inter-H-H 228-228" 231-231"

Modified residues / Résidus modifiés / Resíduos modificados

Substitution ratio of 2 to 5 lysyl (K)
out of the 90 of the antibody molecule
N^6-(^{90}Y-yttrium tetraxetan)-L-lysyl



N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
299, 299"


zoleprodololum

zoleprodolol — (±)-1-(2-[(3-methoxy-1,2,4-oxadiazol-5-yl)methoxy]phenoxy)-3-[(*tert*-butylamino)]propan-2-ol

zoléprodolol — (±)-1-(2-[(3-methoxy-1,2,4-oxadiazol-5-yl)methoxy]phenoxy)-3-[(*tert*-butylamino)]propan-2-ol

zoleprodolol — (±)-1-(2-[(3-metoxi-1,2,4-oxadiazol-5-il)metoxi]fenoxi)-3-[(*terc*-butilamino)]propan-2-ol

$C_{17}H_{25}N_3O_5$



and enantiomer
et énantiomère
y enantiómero

AMENDMENTS TO PREVIOUS LISTS
MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES
MODIFICACIONES A LAS LISTAS ANTERIORES

Proposed International Non Proprietary Names (Prop. INN): List 50
Dénominations communes internationales proposées (DCI Prop.): Liste 50
Denominaciones Comunes Internacionales Propuestas (DCI Prop.): Lista 50
(WHO Drug Information, Vol. 17, No. 4, 2003)


p. 268 **alvocidibum**

alvocidib — *replace the graphic formula and the chemical name by the following ones*
alvocidib — *remplacer la formule développée et le nom chimique par les suivants*
alvocidib — *sustitúyase la fórmula desarrollada y el nombre químico por los siguientes*

(-)-2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3*S*,4*R*)-3-hydroxy-1-methylpiperidin-4-yl]-4*H*-1-benzopyran-4-one

(-)-2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3*S*,4*R*)-3-hydroxy-1-methylpiperidin-4-yl]-4*H*-1-benzopyran-4-one

(-)-2-(2-clorofenil)-5,7-dihidroxi-8-[(3*S*,4*R*)-3-hidroxi-1-metilpiperidin-4-il]-4*H*-1-benzopiran-4-ona



Proposed International Non Proprietary Names (Prop. INN): List 63
Dénominations communes internationales proposées (DCI Prop.): Liste 63
Denominaciones Comunes Internacionales Propuestas (DCI Prop.): Lista 63
(WHO Drug Information, Vol. 24, No. 1, 2010)

p. 43 **aganirsenum**

aganirsen — replace the chemical name by the following
aganirsén — sustitúyase el nombre químico por el siguiente

all-P-ambo-P-thiothymidylyl-(3'→'5')-2'-deoxy-*P*-thioadenylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-deoxy-*P*-thiocytidylyl-(3'→5')-2'-deoxy-*P*-thiocytidylyl-(3'→5')-2'-deoxy-*P*-thioguanylyl-(3'→5')-2'-deoxy-*P*-thioguanylyl-(3'→5')-2'-deoxy-P-thioadenylyl-(3'→5')-2'-deoxy-*P*-thioguanylyl-(3'→5')-2'-deoxy-*P*-thioguanylyl-(3'→5')-2'-deoxy-*P*-thioguanylyl-(3'→5')-2'-deoxy-*P*-thiocytidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')-2'-deoxy-*P*-thioguanylyl-(3'→5')-2'-deoxy-*P*-thiocytidylyl-(3'→5')-2'-deoxy-*P*-thiocytidylyl-(3'→5')-2'-deoxy-*P*-thioadenylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-deoxy-*P*-thioguanylyl-(3'→5')-2'-deoxy-*P*-thiocytidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-deoxy-*P*-thioguanylyl-(3'→5')-2'-deoxy-*P*-thiocytidylyl-(3'→5')-thymidine

todo-P-ambo-P-tiotimidilil-(3'→5')-2'-desoxi-*P*-tioadenilil-(3'→5')-*P*-tiotimidilil-(3'→5')-2'-desoxi-*P*-tiocitidilil-(3'→5')-2'-desoxi-*P*-tiocitidilil-(3'→5')-2'-desoxi-*P*-tioguanilil-(3'→5')-2'-desoxi-*P*-tioguanilil-(3'→5')-2'-desoxi-*P*-tioadenilil-(3'→5')-2'-desoxi-*P*-tioguanilil-(3'→5')-2'-desoxi-*P*-tioguanilil-(3'→5')-2'-desoxi-*P*-tioguanilil-(3'→5')-2'-desoxi-*P*-tiocitidilil-(3'→5')-*P*-tiotimidilil-(3'→5')-2'-desoxi-*P*-tiocitidilil-(3'→5')-2'-desoxi-*P*-tioguanilil-(3'→5')-2'-desoxi-*P*-tiocitidilil-(3'→5')-2'-desoxi-*P*-tiocitidilil-(3'→5')-2'-desoxi-*P*-tioadenilil-(3'→5')-*P*-tiotimidilil-(3'→5')-2'-desoxi-*P*-tioguanilil-(3'→5')-2'-desoxi-*P*-tiocitidilil-(3'→5')-*P*-tiotimidilil-(3'→5')-2'-desoxi-*P*-tioguanilil-(3'→5')-2'-desoxi-*P*-tiocitidilil-(3'→5')-timidina

p. 46 **bixalomerum**

bixalomer bixalomère bixalómero	replace the chemical name by the following remplacer le nom chimique par le suivant sustitúyase el nombre químico por el siguiente
	cross linked polymer made of *N*,*N*,*N′*,*N′*-tetrakis(3-aminopropyl)butane-1,4-diamine *N* substituted by bivalent substituent groups 2-hydroxypropane-1,3-diyl and 1-(hydroxymethyl)ethylene (x=20, 45≤y≤50)
	N,*N*,*N′*,*N′*-tétrakis(3-aminopropyl)butane-1,4-diamine *N* substituée par les groupes substituants divalents 2-hydroxypropane-1,3-diyle et 1-(hydroxyméthyl)éthane-1,2-diyle pour former un polymère réticulé (x=20, 45≤y≤50)
	N,*N*,*N′*,*N′*-tétrakis(3-aminopropil)butano-1,4-diamina *N* sustituida por los grupos sustituyentes divalentes 2-hidroxipropano-1,3-diilo y 1-(hidroximetil)etileno para formar un polímero reticulado (x=20, 45≤y≤50)

p. 63

delete/supprimer/suprimáse	insert/insérer/insértese
isopropylis turofexoras	**turofexoras isopropylis**
isopropyl de turofexorate	turofexorate d'isopropyle

Electronic structure available on Mednet: http://mednet.who.int/
Structure electronique disponible sur Mednet: http://mednet.who.int/
Estructura electrónica disponible en Mednet: http://mednet.who.int/

Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios generales

The text of the *Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances* and *General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical Substances* will be reproduced in proposed INN lists only.

Les textes de la *Procédure à suivre en vue du choix de dénominations communes internationales recommandées pour les substances pharmaceutiques* et des *Directives générales pour la formation de dénominations communes internationales applicables aux substances pharmaceutiques* seront publiés seulement dans les listes des DCI proposées.

El texto de los *Procedimientos de selección de denominaciones comunes internacionales recomendadas para las sustancias farmacéuticas* y de los *Principios generales de orientación para formar denominaciones comunes internacionales para sustancias farmacéuticas* aparece solamente en las listas de DCI propuestas.